Please login to the form below

Not currently logged in

Merck says drug for CMV in transplant patients hits targets

Letermovir on course for fast-track 2017 filing and head start in prospective $350m market

Merck & Co says its letermovir drug for preventing an opportunistic infection in transplant patients has hit its targets, setting the project on course for a possible filing in 2017.

Letermovir (AIC426) is being tested for prophylaxis of cytomegalovirus (CMV) activation in patients receiving haematopoietic stem cell transplants - an indication which according to Credit Suisse forecasts could make it a $350m market by the end of the decade.

Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA.

There is a significant need for additional medicines for the treatment of CMV infection, which is one of the most common viral infections affecting transplant patients.

CMV is a herpes virus, infecting 50-90% of the adult population, with a majority remaining without symptoms. However, without preventive drugs approximately 80% of CMV-seropositive patients experience CMV infection after an allogeneic (donor) HSCT, which can lead to organ damage and symptoms such as visual impairment, pneumonia and hepatitis.

Current drugs such as valganciclovir target CMV DNA polymerase and tend to be associated with poor oral bioavailability, the development of resistance and dose-limiting toxicities such as kidney damage and anaemia.

Letermovir goes after another enzyme - viral terminase - and so could provide another line of therapy for resistant infections, while data from a phase II trial suggests it also has a good tolerability profile.

Merck licensed the rights to develop and commercialize letermovir - along with a back-up candidate and other early-stage candidates that act against CMV via an alternate mechanism - from Germany's AiCuris in 2012.

AiCuris - which was formed as a spin-out from Bayer's anti-infectives unit in 2006 - pocketed an upfront payment of €110m and - with milestone payments - could get up to €442.5m plus royalties from Merck.

Merck hasn't given any details yet on the phase III trial results, saying it will submit them for presentation at a future medical conference.

The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of pivotal trials.

Other companies developing CMV-targeting drugs include Atara Biotherapeutics and ViraCyte, which have CMV-specific T-cell therapies in development, while Shire has a small-molecule drug called maribavir heading into phase III testing that it acquired along with ViroPharma in 2013.

Meanwhile, Sanofi, GlaxoSmithKline/AlphaVax, Astellas, Helocyte, Vical and VBI Vaccines have preventive vaccines against the virus in clinical testing.

Article by
Phil Taylor

20th October 2016

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...